Showing results (1611-1620 of 1,641) with videos related to

Sort By:
Pageof 165
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 11, 2025
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancerP Harter, F Trillsch, A Okamoto, et al.
Plos Medicine|December 28, 2023
Procedural sedation and analgesia versus general anesthesia for hysteroscopic myomectomy (PROSECCO trial): A multicenter randomized controlled trialJulia F van der Meulen, Marlies Y Bongers, Lisa G van der Zee, et al.
BMC Pregnancy and Childbirth|March 17, 2012
Progestogens to prevent preterm birth in twin pregnancies: an individual participant data meta-analysis of randomized trialsEwoud Schuit, Sarah Stock, Rolf H H Groenwold, et al.
Nature Communications|May 19, 2022
A bio-functional polymer that prevents retinal scarring through modulation of NRF2 signalling pathwayBhav Harshad Parikh, Zengping Liu, Paul Blakeley, et al.
Science Translational Medicine|June 23, 2012
The structural basis for serotype-specific neutralization of dengue virus by a human antibodyEe Ping Teoh, Petra Kukkaro, En Wei Teo, et al.
Environmental Research|October 23, 2025
Expert perspectives on exposure-response functions for urban health policy: Lessons from a UBDPolicy workshopHarry Williams, Zorana Jovanovic Andersen, Hanna Boogaard, et al.
The Lancet Regional Health. Western Pacific|February 9, 2024
Age-specific breast and ovarian cancer risks associated with germline BRCA1 or BRCA2 pathogenic variants - an Asian study of 572 familiesWeang-Kee Ho, Nur Tiara Hassan, Sook-Yee Yoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2022
Predicting the Likelihood of Carrying a BRCA1 or BRCA2 Mutation in Asian Patients With Breast CancerBoon Hong Ang, Weang Kee Ho, Eldarina Wijaya, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 4, 2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancerRobert W Holloway, Premal Thaker, Alberto A Mendivil, et al.
Pageof 165